Author

Seul Lee

Observed names: S. I. Lee, Seul LEE, Seul-Gi Lee

Institution: Ajou University

Observed institutions: Yonsei University, Samsung Medical Center, Yonsei University Health System, Ajou University

ORCID: 0000-0002-3325-1346

Observed ORCID: 0000-0002-3325-1346

OpenAlex ID: A5046997486

A preceding airway reaction to one allergen may lead to priming of the airway responses to another allergen

1997 · Y. Y. Koh, J.W. Choi, et al. · Allergy · 15

Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing

2024 · Seul Lee, Yunjoo Joo, et al. · PLoS ONE · 8

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2024 · Dong Kwon Kim, Chun-Bong Synn, et al. · Molecular Cancer Therapeutics · 4

A Comprehensive Analysis of HLA-A and HLA-DR Allele Frequencies and Haplotype Associations in a Korean Population of 790 Individuals

2024 · Hee-Kyung HAN, Mi Hyun KIM, et al. · Korean Journal of Clinical Laboratory Science · 2

Figure S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S16 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S6 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Table S1 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S7 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S12 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S1 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S4 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S10 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S11 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S5 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S14 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S9 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S15 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S17 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S3 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S13 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Figure S8 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2026 · Dong Kwon Kim, Chun-Bong Synn, et al.

Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancer

2026 · Seul-Gi Lee, Myungjee Lee, et al. · Journal of Biological Engineering

Figure S11 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2025 · Dong Kwon Kim, Chun-Bong Synn, et al.

Table S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

2025 · Dong Kwon Kim, Chun-Bong Synn, et al.

Works count: 43

Citation count: 29

H-index: 3

I10-index: 1